Citadel Advisors’s Biohaven BHVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$380K Sell
44,900
-95,400
-68% -$1.04M ﹤0.01% 9926
2025
Q4
$1.58M Buy
140,300
+40,200
+40% +$498K ﹤0.01% 6392
2025
Q3
$1.5M Buy
100,100
+22,600
+29% +$329K ﹤0.01% 6670
2025
Q2
$1.09M Buy
77,500
+35,000
+82% +$624K ﹤0.01% 6899
2025
Q1
$1.02M Sell
42,500
-27,300
-39% -$963K ﹤0.01% 6909
2024
Q4
$2.61M Buy
69,800
+19,500
+39% +$910K ﹤0.01% 5093
2024
Q3
$2.51M Buy
50,300
+23,500
+88% +$914K ﹤0.01% 5093
2024
Q2
$930K Sell
26,800
-8,300
-24% -$328K ﹤0.01% 6735
2024
Q1
$1.92M Buy
35,100
+22,100
+170% +$1.09M ﹤0.01% 5607
2023
Q4
$556K Sell
13,000
-22,900
-64% -$712K ﹤0.01% 7869
2023
Q3
$934K Sell
35,900
-31,100
-46% -$646K ﹤0.01% 6701
2023
Q2
$1.6M Buy
67,000
+36,500
+120% +$628K ﹤0.01% 5565
2023
Q1
$417K Sell
30,500
-28,400
-48% -$452K ﹤0.01% 8678
2022
Q4
$818K Buy
+58,900
New +$832K ﹤0.01% 7202

Other funds holding BHVN

Citadel Advisors's BHVN Position: Q1 2026 in Review

Citadel Advisors reduced its Biohaven (BHVN) stake by 1.2% in Q1 2026, selling an estimated $228K and leaving 1,723,107 shares worth $14.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2721.

Citadel Advisors first reported a position in BHVN in Q4 2022 and has held it in 14 quarters since. The position peaked at $87.7M in Q3 2024. 275 funds tracked by Wall St. Rank hold BHVN as of Q1 2026.

  • Citadel Advisors held 1,723,107 shares of Biohaven worth $14.6M as of Q1 2026.
  • Citadel Advisors sold 20,886 Biohaven shares in Q1 2026, an estimated $228K.
  • Biohaven made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2721 holding.
  • Citadel Advisors first reported a position in Biohaven in Q4 2022 and has held it in 14 quarters since.
  • Citadel Advisors's Biohaven position peaked at $87.7M in Q3 2024.
  • 275 funds tracked by Wall St. Rank held Biohaven as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.